Drug Trial Radar · NCT02772276
Pharmacokinetics of MB-102 and Use of the Non-invasive Optical Renal Function Monitor (ORFM) Device in Subjects With Normal and Impaired Renal Function and a Range of Skin Color Types
Last checked: Nov 20, 2026Latest source record: Oct 26, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
234
Actual
Start
May 11, 2016
Primary completion
Aug 4, 2021
Study completion Aug 4, 2021
Sponsor
- Lead sponsor
- MediBeaconIndustry
- Sponsor type
- Industry
- First posted
- May 13, 2016
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study was a pilot, safety, and pharmacokinetic study of MB-102 versus iohexol and the use of the non-invasive optical renal function monitor (ORFM) device in normal and compromised renal function participants with different skin color types.
Conditions
- Acute Kidney Injury
Interventions
MB-102-- single dose of 4 µmol/kgDrug
4 µmol/kg administered by intravenous injection over 30 seconds, followed by a 10 mL normal saline flush administered intravenously over 30 seconds.
MB-102-- single dose of 130 mgDrug
130 mg administered by intravenous injection over 30 seconds, followed by a 10 mL normal saline flush administered intravenously over 30 seconds. A subset of participants will receive two doses of MB-102, 12 hours apart.
MB-102-single dose of 130 mg or 2 doses of 130 mg 12 hours apartDrug
130 mg administered by intravenous injection over 30 seconds, followed by a 10 mL normal saline flush administered intravenously over 30 seconds.
MB-102-- two doses of 130 mg 24 hours apartDrug
4 µmol/kg administered by intravenous injection over 30 seconds, followed by a 10 mL normal saline flush administered intravenously over 30 seconds. A subset of participants will receive two doses of MB-102, 12 hours apart.
IohexolDrug
5 mL of a 647 mg/mL solution administered by intravenous injection over 30 seconds, followed by a 10 mL normal saline flush administered intravenously over 30 seconds
QuantumLeapDevice
Optical Renal Function Monitor (ORFM)
RadianceDevice
Optical Renal Function Monitor (ORFM)
Brilliance (1 or 2 sensors)Device
Optical Renal Function Monitor (ORFM)
Brilliance (2-part sensor)Device
Optical Renal Function Monitor (ORFM)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment-Emergent Adverse EventsTime frame: From the time of dosing through the follow-up visit, up to 10 days
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Riverside Clinical Research
Edgewater, Florida
Orlando Clinical Research Center
Orlando, Florida
Washington University School of Medicine
St Louis, Missouri
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.